595 completed, 52 terminated, 22 recruiting, 17 active not recruiting. 201 Phase 2, 182 Phase 1, 166 Phase 3, 94 Phase 4, 22 Not applicable.
Follow Astellas Pharma Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FLT3-ITD Targeted Therapy in Fit AML Patients Gilteritinib, Venetoclax, Azacitidine (AZA) - AML (Acute Myeloid Leukemia) | Phase 2 / Phase 3 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 230 | 2026-12-01 | 2026-02-23 |
| A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause Fezolinetant - Hot Flashes | Phase 3 | Not yet recruiting | Astellas Pharma Inc | 100 | 2026-10-31 | 2026-09-28 |
| Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC Enfortumab Vedotin, Pembrolizumab, Radiation - Urothelial Bladder Cancer | Phase 2 | Not yet recruiting | The Netherlands Cancer Institute | 56 | 2026-09-01 | 2026-06-25 |
| Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers Zolbetuximab, mFOLFOX6, CAPOX - Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | Midhun Malla | 32 | 2026-08-01 | 2026-07-24 |
| AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas Tislelizumab, Leucovorin, Oxaliplatin - Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | American Association for Cancer Research | 242 | 2026-07-20 | 2026-10-05 |
| Study of EV for Recurrent Endometrial Carcinoma Enfortumab Vedotin - Endometrial Cancer | Phase 2 | Recruiting | William Bradley | 12 | 2026-07-10 | 2026-10-16 |
| A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke ASP2246, Brain surgery, Sham surgery - Chronic Ischemic Stroke | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Inc | 84 | 2026-04-03 | 2026-07-09 |
| Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance ASP3082 - Metastatic/Locally Advanced Non-Small-Cell Lung Cancer, Metastatic/Locally Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 60 | 2026-03-25 | 2026-08-05 |
| Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer PF-08634404, Enfortumab Vedotin - Urothelial Cancer, Advanced/Metastatic Urothelial Cancer | Phase 1 / Phase 2 | Recruiting | Pfizer | 132 | 2026-03-11 | 2026-10-08 |
| Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy Enfortumab vedotin - Advanced Small Bowel Adenocarcinoma | Phase 2 | Recruiting | National Cancer Center, Japan | 27 | 2025-11-04 | 2026-03-11 |
| Akyva First In Human Direct Bladder Wall Stimulation - Underactive Bladder | Not applicable | Recruiting | Iota Biosciences, Inc | 15 | 2025-09-24 | 2026-09-14 |
| A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors ASP5834, panitumumab - Solid Tumor, Non-Small-Cell Lung Cancer | Phase 1 | Recruiting | Astellas Pharma Inc | 404 | 2025-07-25 | 2026-10-13 |
| Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria Prostate Cancer, Prostate Cancer (Diagnosis) | Recruiting | Société Algérienne de Formation et Recherche en Oncologie | 2000 | 2025-07-21 | 2026-04-17 | |
| A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC) Enzalutamide, Apalutamide - Metastatic Castration Sensitive Prostate Cancer (mCSPC), Cancer of the Prostate | Completed | Pfizer | 1300 | 2025-07-21 | 2025-12-08 | |
| A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration avacincaptad pegol - Geographic Atrophy, Age-Related Macular Degeneration | Phase 4 | Active not recruiting | Astellas Pharma Inc | 17 | 2025-07-08 | 2026-09-30 |
| PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients enfortumab vedotin, pembrolizumab - Melanoma | Phase 2 | Active not recruiting | Grupo Español Multidisciplinar de Melanoma | 60 | 2025-06-10 | 2026-09-18 |
| Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer Enfortumab vedotin, Pembrolizumab - Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | Matthew Galsky | 75 | 2025-04-07 | 2026-08-05 |
| Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC Enfortumab Vedotin - Metastatic Colorectal Cancer, Hepatocellular Carcinoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 40 | 2025-04-01 | 2026-04-01 |
| Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT) - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 47 | 2025-03-31 | 2026-10-01 |
| Relugolix + Enzalutamide Study in High-Risk Prostate Cancer Relugolix and Enzalutamide - Androgen Deprivation Therapy, Locally Advanced Prostate Cancer | Phase 1 | Recruiting | University of Oklahoma | 46 | 2024-12-26 | 2026-03-05 |
Showing 20 of 717. Sign in to see all of them.
Prostatic Neoplasms (56) · Urinary Bladder, Overactive (47) · Diabetes Mellitus, Type 2 (31) · Arthritis, Rheumatoid (23) · Diabetes Mellitus (20) · Renal Insufficiency, Chronic (20) · Dermatitis, Atopic (16) · Coronary Artery Disease (14) · Neoplasms (14) · Psoriasis (14) · Carcinoma, Non-Small-Cell Lung (13) · Kidney Failure, Chronic (13) · Renal Insufficiency (13) · Urinary Incontinence (13) · Leukemia, Myeloid, Acute (12)
Tacrolimus (96) · enzalutamide (56) · ipragliflozin (41) · mirabegron (39) · Solifenacin Succinate (35) · Mycophenolic Acid (31) · Micafungin (23) · peficitinib (23) · Alefacept (17) · Prednisone (17) · roxadustat (17) · enfortumab vedotin (16) · regadenoson (14) · ramosetron (11) · Adrenal Cortex Hormones (10)
United States (295) · Japan (226) · France (90) · Canada (82) · United Kingdom (82) · Germany (81) · Spain (80) · Belgium (72) · Poland (64) · Italy (60) · Netherlands (53) · Czechia (51) · South Korea (47) · Hungary (45) · Russia (38)
PMID 31606880, PMID 36005278, PMID 37160401, PMID 33068028, PMID 32792252, PMID 38363463, PMID 24246044, PMID 33929089, PMID 35643841, PMID 35731340, PMID 40576086, PMID 21147825, PMID 21293089, PMID 23959319, PMID 25917876, PMID 29149958, PMID 30189902, PMID 31830211, PMID 32839028, PMID 34429152, PMID 34518652, PMID 37185921, PMID 38421243, PMID 12176626, PMID 12176628, PMID 12270445, PMID 14966405, PMID 15233820, PMID 15691277, PMID 15919463, PMID 16316335, PMID 16678903, PMID 16771810, PMID 17175311, PMID 17387127, PMID 17660033, PMID 17919618, PMID 18192906, PMID 18268144, PMID 18703470, PMID 18983417, PMID 19101754, PMID 19143854, PMID 19307792, PMID 19398376, PMID 19744616, PMID 19777549, PMID 19778673, PMID 19804626, PMID 19930331
2009 (15), 2008 (14), 2014 (3), 2023 (3), 2025 (3), 2004 (1), 2005 (1), 2015 (1), 2016 (1), 2017 (1), 2019 (1), K23HL093118 (1), P30CA016672 (1), P30CA093373 (1), P30CA138292 (1)